Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).
Bibliographic record
Abstract
Abstract Abstract #1137 Aim: To investigate the management of bone health in postmenopausal women with early breast cancer (BCA) scheduled to receive anastrozole. Methods: Postmenopausal women with hormone receptor-positive early BCA were assigned to 1 of 3 strata depending on their pre-existing risk of fragility fracture. Patients (pts) with a bone mineral density (BMD) T-score <-2.0 for either spine or hip, or those pts deemed by the investigator to be at increased risk of fracture, were designated higher-risk (H) for fracture and received anastrozole 1 mg/day plus risedronate 35 mg/week orally. Moderate-risk (M) pts (T-score <-1.0 for spine or hip but ≥-2.0 at both sites) were randomized in a double-blind manner to receive anastrozole plus risedronate (A+R) or anastrozole plus placebo (A+P). Pts with T-scores ≥-1.0 at both spine and hip were designated lower-risk (L) and received anastrozole alone. All pts received calcium and vitamin D. Lumbar spine and total hip BMD were assessed at baseline, 12, and 24 months. Results: BMD changes at 24 months are shown in the table. In M, a significant difference in favor of the A+R group compared with the A+P group was seen for both lumbar spine and total hip (both p<0.0001). In H, risedronate therapy was associated with increases in BMD at the lumbar spine (p=0.0006) and total hip (p=0.01). In L, no bisphosphonate therapy was associated with a significant decrease in BMD at the lumbar spine (p=0.01) but not at the total hip. Pts who withdrew did not appear to have an impact on the results. The safety and tolerability profile of anastrozole was similar to that already established and was not significantly altered by the addition of risedronate. Conclusions: In postmenopausal women at risk for fragility fracture receiving adjuvant anastrozole for BCA, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable affects in BMD over 24 months. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1137.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".